Your browser doesn't support javascript.
loading
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network).
Sebbag, Clara; Rousset-Jablonski, Christine; Coussy, Florence; Ray-Coquard, Isabelle; Garin, Clémentine; Evrevin, Clémence; Cessot, Marion; Labrosse, Julie; Laot, Lucie; Darrigues, Lauren; Bobrie, Angélique; Sénéchal-Davin, Claire; Espié, Marc; Giacchetti, Sylvie; Plu-Bureau, Geneviève; Maitrot-Mantelet, Lorraine; Gompel, Anne; Santulli, Pietro; Asselain, Bernard; Hotton, Judicaël; Coutant, Charles; Guerin, Julien; Decanter, Christine; Mailliez, Audrey; Brain, Etienne; Dumas, Elise; Sablone, Laura; Seintinelles, Research Network; Reyal, Fabien; Hamy, Anne-Sophie.
Afiliación
  • Sebbag C; Department of Medical Oncology, Institut Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Université Paris Cité, Paris, France.
  • Rousset-Jablonski C; INSERM U1290 RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.
  • Coussy F; Department of Medical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
  • Ray-Coquard I; INSERM U1290 RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.
  • Garin C; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Evrevin C; Department of Medical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
  • Cessot M; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.
  • Labrosse J; Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
  • Laot L; Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
  • Darrigues L; Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France.
  • Bobrie A; Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France.
  • Sénéchal-Davin C; Department of Oncogenetics, Institut Bergonié, Bordeaux, France.
  • Espié M; Sénolopole, Hôpital Saint Louis, AP-HP, Paris, France; University Paris, Paris France.
  • Giacchetti S; Sénolopole, Hôpital Saint Louis, AP-HP, Paris, France; University Paris, Paris France.
  • Plu-Bureau G; Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France.
  • Maitrot-Mantelet L; Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France.
  • Gompel A; Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France.
  • Santulli P; Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France.
  • Asselain B; Department of Biostatistics, Unicancer, Paris, France.
  • Hotton J; Department of Surgical Oncology, Institut Godinot, Reims, France.
  • Coutant C; Department of Surgical Oncology, Centre Georges-François Leclerc - Unicancer, Dijon, France; Clinical Research Department, Centre Georges-François Leclerc - Unicancer, Dijon, France.
  • Guerin J; Data Factory, Data Office, Institut Curie, 25 rue d'Ulm, 75005 Paris, France.
  • Decanter C; ART department, Centre Hospitalier Regional Lille, Lille, France.
  • Mailliez A; Department of Medical Oncology, Centre Oscar Lambert, Lille, France.
  • Brain E; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
  • Dumas E; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Sablone L; Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France.
  • Seintinelles RN; Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France.
  • Reyal F; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Department of Surgical Oncology, Institut Curie, Paris, France; Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, Fran
  • Hamy AS; Department of Medical Oncology, Institut Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Department of Surgical Oncology, Institut Curie, Paris, France; Seintine
Breast ; 67: 62-70, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36630821
OBJECTIVE: To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls. STUDY DESIGN: The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study, including localized BC patients aged 18-43 years, matched for age and parity to cancer-free volunteer controls in a 1:2 ratio. Data were collected through online questionnaires completed on the Seintinelles research platform. RESULTS: In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p = 0.97). Contrarily, the contraceptive methods used were significantly different, with a higher proportion of copper IUD use in BC survivors (59.5% versus 25.0% in controls p < 0.001). For patients at risk of unintentional pregnancy, receiving information about chemotherapy-induced ovary damage at BC diagnosis (OR = 2.47 95%CI [ 1.39-4.37] and anti-HER2 treatment (OR = 2.46, 95% CI [ 1.14-6.16]) were significantly associated with the use of a contraception in multivariate analysis. CONCLUSION: In this large French study, BC survivors had a prevalence of contraception use similar to that for matched controls, though almost one in five women at risk of unintentional pregnancy did not use contraception. Dedicated consultations at cancer care centers could further improve access to information and contraception counseling.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Supervivientes de Cáncer Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Supervivientes de Cáncer Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos